Search results
1 day ago · Companies like Juno Therapeutics, Tessa Therapeutics, and Adaptimmune are leading the way in this field, with TT-02 and other CAR T-cell therapies showing promise for the treatment of various cancers.
4 days ago · Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, today announced that it has received...
23 hours ago · The Car T-cell therapy market is experiencing significant growth due to the potential of these treatments for blood cancer, specifically lymphoma and leukemia. Companies like Juno Therapeutics and Tessa Therapeutics are leading the charge with their CAR T-cell therapies, TT-02 for solid tumors, and Tessa’s TCR-based therapy for ovarian cancer.
5 days ago · The small molecule COH29 inhibits the production of ribonucleotide reductase (RNR), an enzyme that is central to production of many types of cancer cells. Current clinically-established RNR inhibitors -- such as hydroxyurea and gemcitabine -- have drawbacks, including a short half-life and drug resistance.
5 days ago · Expand your knowledge and skills by exploring the latest data on leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. Authors: Hagop M. Kantarjian, MD; Courtney D. DiNardo, MD, MSCE; Guillermo Garcia-Manero, MD; Elias J. Jabbour, MD; Susan O'Brien, MD; Srdan Verstovsek, MD, PhD. Log In to Start.
3 days ago · Juno Therapeutics is advancing a CAR T-cell therapy, which includes both CD4+ and CD8+ T-cells from the same patient, modified to express a BCMA-specific CAR.
4 days ago · Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill ...
